{"groups":[{"description":"\\- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity\n\n* Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.\n* Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase\n* Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase\n* Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase\n\nIxazomib: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.\n\nDexamethasone: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.\n\nRituximab: Doses given on Day 1 of induction and maintenance cycles.","id":"FG000","title":"Ixazomib, Dexamethasone, Rituximab"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"26"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"26"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}